Key facts
- Definition: the greater insulin secretion after oral glucose than after intravenous glucose at matching blood-glucose levels.
- Main hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
- Where they come from: intestinal L cells (GLP-1) and K cells (GIP), released after eating.
- Off switch: the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates both within minutes.
- Glucose-dependent: the insulin-boosting action mainly operates when blood glucose is elevated.
- In type 2 diabetes: the incretin effect is blunted, with a reduced insulin response to GIP.
- Drug relevance: the basis for GLP-1 receptor agonists and DPP-4 inhibitors.
What is the incretin effect?
The incretin effect is a simple observation with far-reaching consequences: if you swallow a measured dose of glucose, your pancreas releases substantially more insulin than it does when the very same amount of glucose is infused directly into a vein to reach identical blood-glucose levels.
Both routes raise blood sugar the same way, so the extra insulin cannot be explained by glucose alone. Something about food passing through the gut tells the pancreas that carbohydrate is arriving and to prepare for it. That "something" is a set of gut hormones — the incretins — and the surplus insulin they trigger is the incretin effect. In healthy people this gut-driven amplification is thought to account for a large share of the insulin released after a meal, which is why it is central to how the body handles everyday eating rather than a laboratory curiosity.
Understanding this gap between oral and intravenous glucose is what first pointed researchers toward hormones secreted by the intestine, and eventually to the two molecules that dominate the story: GLP-1 and GIP.
GLP-1 and GIP: the two incretin hormones
Two hormones do most of the work. Glucagon-like peptide-1 (GLP-1) is secreted mainly by L cells located in the lower small intestine and colon. Glucose-dependent insulinotropic polypeptide (GIP) is secreted by K cells in the upper small intestine. Both are released within minutes of eating, in response to nutrients — carbohydrate, fat and protein — reaching the gut lining.
Once in the bloodstream, each hormone reaches the insulin-producing beta cells of the pancreas and enhances glucose-stimulated insulin secretion. A crucial feature is that this boosting action is largely glucose-dependent: the incretins amplify insulin release chiefly when blood glucose is elevated, and their insulin-stimulating drive fades as glucose returns toward normal. That built-in dependence on high glucose is part of why the pathway drew interest as a treatment target — it favours insulin release when it is needed most.
GLP-1 and GIP act through their own distinct receptors. The receptor biology behind each is covered in our explainers on the GLP-1 receptor and the GIP receptor. For a molecule-level view of GLP-1's physiology, the classic review by Holst remains a standard reference (PMID 17928588).
How DPP-4 switches incretins off
Left unchecked, a hormone that boosts insulin could keep working long after a meal is over. The body prevents that with an enzyme called dipeptidyl peptidase-4 (DPP-4). DPP-4 clips two amino acids from the end of both GLP-1 and GIP, converting them into forms that no longer stimulate insulin the way the intact hormones do.
This degradation is fast. Native GLP-1 has a circulating half-life measured in only a couple of minutes, because DPP-4 begins inactivating it almost as soon as it is released. The practical result is that the natural incretin signal is powerful but short-lived — a brief pulse timed to the meal, then switched off.
That rapid breakdown is also the pharmacological hinge of the whole field. If natural GLP-1 lasts only minutes, then any drug built around it must either resist DPP-4 or stop DPP-4 from acting. Both approaches exist, and both trace directly back to this enzyme.
The incretin effect in type 2 diabetes
In people with type 2 diabetes, the incretin effect is diminished. An oral glucose load still releases some extra insulin compared with an intravenous load, but far less than in people without diabetes. Research has shown this reduced amplification is a consistent feature of the condition, and it is discussed at length in reviews of the incretin system in type 2 diabetes (PMID 17098089).
The two hormones are not affected equally. A recurring finding is that the pancreas becomes markedly less responsive to the insulin-boosting action of GIP, while it often remains able to respond to GLP-1 when GLP-1 is supplied at higher, pharmacological concentrations. Whether the blunted incretin effect is a cause or a consequence of the diabetic state is not fully settled, but the preserved responsiveness to GLP-1 is what made GLP-1 an especially attractive drug target: the machinery it acts on is still functional.
How incretin-based drugs exploit the system
Two distinct drug strategies grew out of incretin physiology, and both are explained by the biology above.
- GLP-1 receptor agonists. These are engineered molecules that activate the GLP-1 receptor but are structurally modified to resist DPP-4 degradation. Because they are not clipped apart within minutes, they can act for hours or, with modern once-weekly designs, across a whole week — sustaining an incretin-like signal far longer than the natural hormone ever could. The drug class is summarised in our overview of GLP-1 receptor agonists.
- DPP-4 inhibitors. Rather than replacing GLP-1, these drugs block the enzyme that destroys it. By inhibiting DPP-4, they raise the circulating levels of a person's own GLP-1 and GIP, prolonging the natural incretin response instead of imposing a synthetic one.
Newer agents extend the idea further by engaging more than one incretin receptor at once — for example combining GLP-1 and GIP activity in a single molecule. The point common to all of them is that they do not invent a new pathway; they lean on the incretin system the body already uses, correcting for the enzyme that would otherwise cut the signal short. This is also the mechanistic thread that connects the incretin story to the broader landscape of peptides for weight loss.
Beyond insulin: GLP-1's wider actions
Although the incretin effect is defined narrowly by insulin secretion, GLP-1 in particular does more than nudge the pancreas. It slows the rate at which the stomach empties, suppresses inappropriate glucagon release when glucose is already high, and acts on receptors in the brain that influence satiety and food intake. Peptide hormones like GLP-1 also feed into the regulation of fat tissue and broader metabolism, an area reviewed in the literature on 21st-century peptide hormones (PMID 34067710).
These additional actions are why drugs built on the incretin system affect appetite and body weight, not only blood sugar — and why a mechanism first described as a quirk of oral versus intravenous glucose now underpins some of the most widely discussed medicines in metabolic health. For the full evidence map, browse the PepMate research library.
Frequently asked questions
What is the incretin effect in simple terms?
The incretin effect is the observation that swallowing glucose triggers a much larger insulin release than infusing the same amount of glucose directly into a vein. The extra insulin is prompted by gut hormones released when food reaches the intestine. Because the gut signals the pancreas that carbohydrate is on the way, the body responds before blood sugar has even fully risen.
Which hormones are responsible for the incretin effect?
Two gut hormones account for most of the incretin effect: glucagon-like peptide-1 (GLP-1), secreted mainly by L cells in the lower small intestine and colon, and glucose-dependent insulinotropic polypeptide (GIP), secreted by K cells in the upper small intestine. Both are released in response to nutrients and both enhance glucose-stimulated insulin secretion from the pancreas.
What does DPP-4 do to incretin hormones?
Dipeptidyl peptidase-4 (DPP-4) is an enzyme that clips two amino acids off the end of GLP-1 and GIP, inactivating them within minutes of release. This is why native GLP-1 has a half-life of only a couple of minutes. DPP-4 is the reason the incretin signal is normally brief, and it is the target that DPP-4 inhibitor drugs block to make natural incretins last longer.
Why is the incretin effect reduced in type 2 diabetes?
In type 2 diabetes the incretin effect is diminished, so an oral glucose load produces less of the extra insulin release seen in people without diabetes. Research points to a reduced insulin-boosting response to GIP in particular, while the pancreas often remains responsive to GLP-1 when it is supplied at higher, pharmacological levels. That preserved GLP-1 responsiveness is part of why GLP-1-based therapies were pursued.
How do incretin-based drugs use this pathway?
Two strategies exploit the incretin system. GLP-1 receptor agonists are engineered molecules that activate the GLP-1 receptor and resist DPP-4 breakdown, so they act far longer than natural GLP-1. DPP-4 inhibitors instead block the enzyme that degrades incretins, raising the levels of a person's own GLP-1 and GIP. Newer agents also engage the GIP receptor alongside GLP-1.
Is the incretin effect only about insulin?
No. Although the incretin effect is defined by insulin secretion, GLP-1 in particular has broader actions: it slows gastric emptying, suppresses the release of glucagon when glucose is high, and acts on the brain to increase satiety. These additional effects are part of why GLP-1 receptor agonists influence appetite and body weight, not only blood sugar.
Sources
This summary traces to peer-reviewed reviews of incretin physiology:
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes — Lancet, 2006; PubMed 17098089.
- The physiology of glucagon-like peptide 1 — Physiological Reviews, 2007; PubMed 17928588.
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Adipose Tissue Functions — Genes (Basel), 2021; PubMed 34067710.
- Background reference: incretin.